Inovio Pharma (INO) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Maxim Group Upgrades Inovio Pharmaceuticals (INO) to Buy
March 16, 2017 7:28 AM EDTMaxim Group upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Hold to Buy with a price target of $10.00.
Analyst Jason McCarthy highlighted:
Inovio reported YE16 with $35M in revenue (grants, collaborations) and $112M in operating expenses for a net loss of $74M. The company ended the year with $105M in cash. We expect Inovio will continue to receive grant and collaborative revenue in 2017 which will partially offset operating expenses.... More